ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
A research team has established a CRISPR/Cas9 gene-editing system for Chrysanthemum morifolium, targeting the CmPDS gene to explore gene functions and enhance breeding. By combining transient and ...
In the present study, we investigated whether electroporation could be used for one-step multiplex CRISPR/Cas9-based genome editing, targeting IL2RG and GHR in porcine embryos. First, we evaluated and ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive enzymes towards invading bacteriophages that express ...
An appeals court has opened another chapter in the long-running CRISPR patent saga. Three years after a patent body ruled in favor of the teams behind Editas Medicine’s intellectual property, an ...
Young adult mice with a genetic form of progressive deafness can hear again after being treated with an experimental CRISPR gene therapy that its creators hope to eventually use in humans. In an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback